|
1
|
Angoulvant D, Ivanes F, Ferrera R,
Matthews PG, Nataf S and Ovize M: Mesenchymal stem cell conditioned
media attenuates in vitro and ex vivo myocardial reperfusion
injury. J Heart Lung Transplant. 30:95–102. 2011. View Article : Google Scholar
|
|
2
|
Preda MB, Rønningen T, Burlacu A,
Simionescu M, Moskaug JØ and Valen G: Remote transplantation of
mesenchymal stem cells protects the heart against
ischemia-reperfusion injury. Stem Cells. 32:2123–2134. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Y, Abarbanell AM, Herrmann JL, Weil
BR, Manukyan MC, Poynter JA and Meldrum DR: TLR4 inhibits
mesenchymal stem cell (MSC) STAT3 activation and thereby exerts
deleterious effects on MSC-mediated cardioprotection. PloS One.
5:e142062010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dexheimer V, Mueller S, Braatz F and
Richter W: Reduced reactivation from dormancy but maintained
lineage choice of human mesenchymal stem cells with donor age. PloS
One. 6:e229802011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kanawa M, Igarashi A, Ronald VS, Higashi
Y, Kurihara H, Sugiyama M, Saskianti T, Pan H and Kato Y:
Age-dependent decrease in the chondrogenic potential of human bone
marrow mesenchymal stromal cells expanded with fibroblast growth
factor-2. Cytotherapy. 15:1062–1072. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maioli M, Contini G, Santaniello S,
Bandiera P, Pigliaru G, Sanna R, Rinaldi S, Delitala AP, Montella
A, Bagella L and Ventura C: Amniotic fluid stem cells morph into a
cardiovascular lineage: Analysis of a chemically induced cardiac
and vascular commitment. Drug Des Devel Ther. 7:1063–1073.
2013.PubMed/NCBI
|
|
7
|
Rennie K, Gruslin A, Hengstschläger M, Pei
D, Cai J, Nikaido T and Bani-Yaghoub M: Applications of amniotic
membrane and fluid in stem cell biology and regenerative medicine.
Stem Cells Int. 2012:7215382012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng AS and Yau TM: Paracrine effects of
cell transplantation: Strategies to augment the efficacy of cell
therapies. Semin Thorac Cardiovasc Surg. 20:94–101. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang M, Methot D, Poppa V, Fujio Y, Walsh
K and Murry CE: Cardiomyocyte grafting for cardiac repair: Graft
cell death and anti-death strategies. J Mol Cell Cardiol.
33:907–921. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Balsam LB, Wagers AJ, Christensen JL,
Kofidis T, Weissman IL and Robbins RC: Haematopoietic stem cells
adopt mature haematopoietic fates in ischaemic myocardium. Nature.
428:668–673. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hammerman PS, Fox CJ, Birnbaum MJ and
Thompson CB: Pim and Akt oncogenes are independent regulators of
hematopoietic cell growth and survival. Blood. 105:4477–4483. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim SJ, Cheon SH, Yoo SJ, Kwon J, Park JH,
Kim CG, Rhee K, You S, Lee JY, Roh SI and Yoon HS: Contribution of
the PI3K/Akt/PKB signal pathway to maintenance of self-renewal in
human embryonic stem cells. FEBS Lett. 579:534–540. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Catalucci D and Condorelli G: Effects of
Akt on cardiac myocytes: Location counts. Circ Res. 99:339–341.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lim SY, Kim YS, Ahn Y, Jeong MH, Hong MH,
Joo SY, Nam KI, Cho JG, Kang PM and Park JC: The effects of
mesenchymal stem cells transduced with Akt in a porcine myocardial
infarction model. Cardiovasc Res. 70:530–542. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mangi AA, Noiseux N, Kong D, He H, Rezvani
M, Ingwall JS and Dzau VJ: Mesenchymal stem cells modified with Akt
prevent remodeling and restore performance of infarcted hearts. Nat
Med. 9:1195–1201. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu YS, Shen ZY, Ye WX, Huang HY, Hua F,
Chen YH, Chen K, Lao WJ and Tao L: AKT-modified autologous
intracoronary mesenchymal stem cells prevent remodeling and repair
in swine infarcted myocardium. Chin Med J (Engl). 123:1702–1708.
2010.
|
|
17
|
Fei X, Jiang S, Zhang S, Li Y, Ge J, He B,
Goldstein S and Ruiz G: Isolation, culture and identification of
amniotic fluid-derived mesenchymal stem cells. Cell Biochem
Biophys. 67:689–694. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang S, Zhang M, Goldstein S, Li Y, Ge J,
He B and Ruiz G: The effect of c-fos on acute myocardial infarction
and the significance of metoprolol intervention in a rat model.
Cell Biochem Biophys. 65:249–255. 2013. View Article : Google Scholar
|
|
19
|
Zhang S, Liu X, Goldstein S, Li Y, Ge J,
He B, Fei X, Wang Z and Ruiz G: Role of the JAK/STAT signaling
pathway in the pathogenesis of acute myocardial infarction in rats
and its effect on NF-κB expression. Mol Med Rep. 7:93–98. 2013.
|
|
20
|
Chen C, Xu Y and Song Y: IGF-1
gene-modified muscle-derived stem cells are resistant to oxidative
stress via enhanced activation of IGF-1R/PI3K/AKT signaling and
secretion of VEGF. Mol Cell Biochem. 386:167–175. 2014. View Article : Google Scholar
|
|
21
|
Takashima S, Tempel D and Duckers HJ:
Current outlook of cardiac stem cell therapy towards a clinical
application. Heart. 99:1772–1784. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kunisaki SM, Fuchs JR, Steigman SA and
Fauza DO: A comparative analysis of cartilage engineered from
different perinatal mesenchymal progenitor cells. Tissue Eng.
13:2633–2644. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kolambkar YM, Peister A, Soker S, Atala A
and Guldberg RE: Chondrogenic differentiation of amniotic
fluid-derived stem cells. J Mol Histol. 38:405–413. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lanfranchi A, Porta F and Chirico G: Stem
cells and the frontiers of neonatology. Early Hum Dev. 85(Suppl
10): S15–S18. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Davydova DA: Stem cells in human amniotic
fluid. Izv Akad Nauk Ser Biol. 517–526. 2010.In Russian.
|
|
26
|
Sessarego N, Parodi A, Podestà M,
Benvenuto F, Mogni M, Raviolo V, Lituania M, Kunkl A, Ferlazzo G,
Bricarelli FD, et al: Multipotent mesenchymal stromal cells from
amniotic fluid: Solid perspectives for clinical application.
Haematologica. 93:339–346. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou J, Wang D, Liang T, Guo Q and Zhang
G: Amniotic fluid-derived mesenchymal stem cells: Characteristics
and therapeutic applications. Arch Gynecol Obstet. 290:223–231.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Baulier E, Favreau F, Le Corf A, Jayle C,
Schneider F, Goujon JM, Feraud O, Bennaceur-Griscelli A, Hauet T
and Turhan AG: Amniotic fluid-derived mesenchymal stem cells
prevent fibrosis and preserve renal function in a preclinical
porcine model of kidney transplantation. Stem Cells Transl Med.
3:809–820. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Skardal A, Mack D, Kapetanovic E, Atala A,
Jackson JD, Yoo J and Soker S: Bioprinted amniotic fluid-derived
stem cells accelerate healing of large skin wounds. Stem Cells
Transl Med. 1:792–802. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zheng YB, Zhang XH, Huang ZL, Lin CS, Lai
J, Gu YR, Lin BL, Xie DY, Xie SB, Peng L and Gao ZL:
Amniotic-fluid-derived mesenchymal stem cells overexpressing
interleukin-1 receptor antagonist improve fulminant hepatic
failure. PloS One. 7:e413922012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Villani V, Milanesi A, Sedrakyan S, Da
Sacco S, Angelow S, Conconi MT, Di Liddo R, De Filippo R and Perin
L: Amniotic fluid stem cells prevent β-cell injury. Cytotherapy.
16:41–55. 2014. View Article : Google Scholar
|
|
32
|
Yeh YC, Wei HJ, Lee WY, Yu CL, Chang Y,
Hsu LW, Chung MF, Tsai MS, Hwang SM and Sung HW: Cellular
cardiomyoplasty with human amniotic fluid stem cells: In vitro and
in vivo studies. Tissue Eng Part A. 16:1925–1936. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bollini S, Pozzobon M, Nobles M, Riegler
J, Dong X, Piccoli M, Chiavegato A, Price AN, Ghionzoli M, Cheung
KK, et al: In vitro and in vivo cardiomyogenic differentiation of
amniotic fluid stem cells. Stem Cell Rev. 7:364–380. 2011.
View Article : Google Scholar
|
|
34
|
Lee WY, Wei HJ, Lin WW, Yeh YC, Hwang SM,
Wang JJ, Tsai MS, Chang Y and Sung HW: Enhancement of cell
retention and functional benefits in myocardial infarction using
human amniotic-fluid stem-cell bodies enriched with endogenous ECM.
Biomaterials. 32:5558–5567. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Murphy E and Steenbergen C: Mechanisms
underlying acute protection from cardiac ischemia-reperfusion
injury. Physiol Rev. 88:581–609. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gnecchi M, He H, Noiseux N, Liang OD,
Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS and Dzau
VJ: Evidence supporting paracrine hypothesis for Akt-modified
mesenchymal stem cell-mediated cardiac protection and functional
improvement. FASEB J. 20:661–669. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ellison GM, Torella D, Dellegrottaglie S,
Perez-Martinez C, Perez de Prado A, Vicinanza C, Purushothaman S,
Galuppo V, Iaconetti C, Waring CD, et al: Endogenous cardiac stem
cell activation by insulin-like growth factor-1/hepatocyte growth
factor intracoronary injection fosters survival and regeneration of
the infarcted pig heart. J Am Coll Cardiol. 58:977–986. 2011.
View Article : Google Scholar : PubMed/NCBI
|
